Colorectal Cancer in Patients With Inflammatory Bowel Disease: The Need for a Real Surveillance Program

Fornaro, Rosario; Caratto, Michela; Caratto, Elisa; Colella, Giuseppe; Fornaro, Francesco; Giovinazzo, Davide; Sticchi, Camilla; Casaccia, M.; Andorno, Enzo

doi:10.1016/j.clcc.2016.02.002

Cited by 35 publications

(26 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of this project do indicate that a basic, high lymphocyte infiltration, without any other information regarding the characteristics of the lymphocytes other than their presences, as established by an H & E stain, is associated with a worse prognosis. There are many instances, and a large amount of data (Cai et al, ; Demaria et al, ; Dennis et al, ; Dulai, Sandborn, & Gupta, ; Fornaro et al, ; Grivennikov, Greten, & Karin, ; McLean et al, ; Pal et al, ; Romaniuk & Lуndіn, ; Viac, Bustamante, & Thivolet, ; Westbrook, Szakmary, & Schiestl, ), supporting the conclusion that inflammation is associated with cancer development, including in the case of endometrial carcinoma (Berstein, ; Trabert et al, ). However, given the association of a good prognosis with the above recovery of TRB recombination reads, as well as with other immune receptor recombination reads, the question becomes, which type of lymphocytes is associated with a poor prognosis?…”

Section: Discussionmentioning

confidence: 91%

TRB‐J1 usage, in combination with the HLA‐A*01:01 allele, represents an apparent survival advantage for uterine corpus endometrial carcinoma: Comparisons with microscopic assessments of lymphocyte infiltrates

Clark

Wei

Callahan

et al. 2018

Int J Immunogenetics

View full text Add to dashboard Cite

Summary The opportunity for the highly efficient recovery of immune receptor recombination data from cancer specimens, including the ready assessment of immune receptor V and J usage, raises the issue of establishing precise values of assessing the immune receptor status as opposed to obtaining basic information regarding lymphocyte infiltration, in the cancer setting. In this report, we obtained the lymphocyte infiltration percentages from the cancer digital slide archive representing uterine corpus endometrial carcinoma (UCEC) and correlated these data with recovery of the immune receptor recombination reads from corresponding UCEC exome files. Results indicated a basic correlation of the recovery of productive T‐cell receptor beta (TRB) recombination reads with lymphocyte infiltration percentages. However, the recovery of specific immune receptor recombination reads did not indicate the same survival outcomes as microscope detection of lymphocyte infiltrate percentages. To further exploit the value of recovery of the TRB recombination reads from the UCEC exome files, we determined the survival outcomes for combinations of TRB gene segment usage and HLA class I alleles, with the most important result being that the combination of HLA‐A*01:01 and TRB‐J1 segment usage reflected a strikingly high survival rate. Overall, this report emphasized the increased value of the knowledge of the immune receptor recombinations, in comparison with basic lymphocyte infiltration percentages, in assessing cancer survival rates.

show abstract

Section: Discussionmentioning

confidence: 91%

TRB‐J1 usage, in combination with the HLA‐A*01:01 allele, represents an apparent survival advantage for uterine corpus endometrial carcinoma: Comparisons with microscopic assessments of lymphocyte infiltrates

Clark

Wei

Callahan

et al. 2018

Int J Immunogenetics

View full text Add to dashboard Cite

show abstract

“…In CD one of the most frequent complications are fistulas, which can arise along the entire gastrointestinal tract, although in most cases they are perianal (54$), enteric (24$), or rectovaginal (9$). One-third of CD patients will have recurrent fistulas that are difficult to manage for both the clinician and the surgeon [4, 5, 6]. The chronic inflammatory process that characterizes this disease exposes CD patients to an increased risk of cancer [7]: they have a risk two to three times higher than the general population [4, 5, 6].…”

Section: Discussionmentioning

confidence: 99%

“…One-third of CD patients will have recurrent fistulas that are difficult to manage for both the clinician and the surgeon [4, 5, 6]. The chronic inflammatory process that characterizes this disease exposes CD patients to an increased risk of cancer [7]: they have a risk two to three times higher than the general population [4, 5, 6]. The different neoplastic transformations and the different types of tumors that may appear in patients with CD, especially at the colorectal level or at the level of an eventual anastomosis, are to date well documented and described in the literature, while there is a lack of information and of treated cases concerning the occurrence of cancer at the level of a fistula (the carcinoma rate is < 1$).…”

Section: Discussionmentioning

confidence: 99%

Adenocarcinoma Arising from Perianal Fistulizing Crohn’s Disease

Fornaro

Frascio

Caratto

et al. 2018

Case Rep Gastroenterol

Self Cite

View full text Add to dashboard Cite

Perianal fistula is a very debilitating event and a cause of morbidity in patients with Crohn’s disease (CD). Its malignant transformation is very rare with an incidence of around 0.004–0.7%. Presence of disease in the colon and rectum is the major risk factor for the development of a perianal fistula. In this report we show a case of adenocarcinoma arising from a perianal fistulizing CD. This type of tumor is highly aggressive, difficult to diagnose, and has a rather poor prognosis. The different neoplastic transformations and the different types of tumors that may appear in patients with CD, especially at the colorectal level or at the level of an eventual anastomosis, are to date well documented and described in the literature, while there is a lack of information and of treated cases concerning the occurrence of cancer at the level of a fistula. Due to the rarity of cases, we tried to identify the most frequent and important risk factors: sex, duration of disease, age at diagnosis, and the history of the fistula.

show abstract

“…The issue of the variable impacts of immune function spans the consideration of the role of the immune system in tumor development. Immune checkpoint inhibitors have had great positive benefits for at least a subset of patients (18), yet in other settings, evidence indicates that inflammation, particularly chronic inflammation, is associated with tumor development (19,20).…”

Section: Resultsmentioning

confidence: 99%

MHC class II associated stomach cancer mutations correlate with lack of subsequent tumor development

Yavorski

Blanck

2017

mol clin onc

View full text Add to dashboard Cite

Abstract. The role of tumor cell expression of major histocompatibility class II (MHCII) has been controversial, with evidence indicating that tumor cell expression of MHCII may lead to an anti-tumor immune response and to tumor cell apoptosis and that MHCII has pro-tumorigenic functions. The cancer genome atlas (TCGA) indicates numerous deleterious mutations for the highly specific, MHCII transcriptional activation proteins, RFX5, RFXAP, RFXANK and CIITA. Also, mutations in the non-polymorphic, human leukocyte antigen (HLA)-DRA gene, which encodes the heavy chain for the most prominent human MHCII molecule, HLA-DR, are common. For many, if not most TCGA cancer datasets, the MHCII specific mutations do not associate with clinical outcomes. However, stomach carcinoma represents an exception, where the data indicate that MHCII-specific mutations are associated with a more favorable outcome. These data raise the question of whether stomach cancer mutations represent effective haploinsufficiency or whether mutations that are associated with a favorable outcome occur with other stomach cancer molecular features that limit the function of the two alleles that represent these MHCII-related proteins.

show abstract

Colorectal Cancer in Patients With Inflammatory Bowel Disease: The Need for a Real Surveillance Program

Cited by 35 publications

References 88 publications

TRB‐J1 usage, in combination with the HLA‐A*01:01 allele, represents an apparent survival advantage for uterine corpus endometrial carcinoma: Comparisons with microscopic assessments of lymphocyte infiltrates

TRB‐J1 usage, in combination with the HLA‐A*01:01 allele, represents an apparent survival advantage for uterine corpus endometrial carcinoma: Comparisons with microscopic assessments of lymphocyte infiltrates

Adenocarcinoma Arising from Perianal Fistulizing Crohn’s Disease

MHC class II associated stomach cancer mutations correlate with lack of subsequent tumor development

Contact Info

Product

Resources

About